Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc. (ZEOX): 3 pipeline candidates · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.4 months
D/E -7.71 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Zeo ScientifiX, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$13.3M
Cash
$1.0M
Quarterly Burn
$471K
Runway
8.4 mo
Revenue
$1.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| cytora novel therapeutic | Phase 2 |
| patient pure x | Preclinical |
| zofin | Preclinical |
Frequently asked questions
How many drug candidates are in Zeo ScientifiX, Inc.'s pipeline?
Zeo ScientifiX, Inc. (ZEOX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Zeo ScientifiX, Inc.'s lead drug candidate?
Zeo ScientifiX, Inc.'s most advanced tracked candidate is cytora novel therapeutic (Phase 2) for Wound care, pain, and orthopedic conditions.
What is Zeo ScientifiX, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Zeo ScientifiX, Inc. has approximately 8.4 months of cash runway.
What is Zeo ScientifiX, Inc.'s market capitalization?
Zeo ScientifiX, Inc.'s market capitalization is approximately $13.3M.
Who is the CEO of Zeo ScientifiX, Inc.?
Mr. Ian T. Bothwell is the chief executive officer of Zeo ScientifiX, Inc. (ZEOX).
Get the full picture on Zeo ScientifiX, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.